{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T17:33:22Z","timestamp":1780508002828,"version":"3.54.1"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:sec>\n            <jats:title>Aim<\/jats:title>\n            <jats:p>The presence of somatostatin receptors in neuroendocrine tumors allows visualization with radiolabeled somatostatin analogs in vivo. The aim of this prospective study was to compare somatostatin receptor imaging using <jats:sup>99m<\/jats:sup>Tc-HYNICTOC with <jats:sup>68<\/jats:sup>Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) with respect to sensitivity, specificity, and impact upon clinical decision making.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Sixty-eight patients (30 men, 38 women; aged 56.4 \u00b1 13.5 years) with disseminated, histologically proven neuroendocrine tumor were enrolled. All patients with previous <jats:sup>99m<\/jats:sup>Tc-HYNICTOC (Tektrotyd; POLATOM, Otwock, Poland) underwent <jats:sup>68<\/jats:sup>Ga-DOTATATE PET\/CT. Both examinations were compared on a per-patient and per-lesion basis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The sensitivity, specificity, positive and negative predictive values, and accuracy of <jats:sup>68<\/jats:sup>Ga-DOTATATE and <jats:sup>99m<\/jats:sup>Tc-HYNICTOC were 100% versus 82%, 85% versus 69%, 97% versus 92%, 100% versus 47%, and 97% versus 79%, respectively.<\/jats:p>\n            <jats:p>Concordant results were observed in 58 patients (49\/68 positive on both <jats:sup>68<\/jats:sup>Ga-DOTATATE and <jats:sup>99m<\/jats:sup>Tc-HYNICTOC and 9\/68 negative in both examinations). Ten of 68 patients had <jats:sup>68<\/jats:sup>Ga-DOTATATE\u2013positive, <jats:sup>99m<\/jats:sup>Tc-HYNICTOC\u2013negative studies. Two hundred eighteen lesions were detected using <jats:sup>99m<\/jats:sup>Tc-HYNICTOC, compared with 546 lesions using <jats:sup>68<\/jats:sup>Ga-DOTATATE (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.0001). <jats:sup>68<\/jats:sup>Ga-DOTATATE detected a higher number of lesions in bone and lymph nodes, liver, intestine, and pancreas and had a higher sensitivity for subcentimeter abnormalities than <jats:sup>99m<\/jats:sup>Tc-HYNICTOC. <jats:sup>68<\/jats:sup>Ga-DOTATATE led to management change in 23 (34%) of 68 patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>\n                                 <jats:sup>68<\/jats:sup>Ga-DOTATATE has a higher sensitivity than <jats:sup>99m<\/jats:sup>Tc-HYNICTOC for the detection of neuroendocrine tumors. <jats:sup>68<\/jats:sup>Ga-DOTATATE proved superior to <jats:sup>99m<\/jats:sup>Tc-HYNICTOC in detecting subcentimeter skeletal, lymph node, and liver metastases. <jats:sup>68<\/jats:sup>Ga-DOTATATE PET\/CT changed clinical decision making in one third of patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000001877","type":"journal-article","created":{"date-parts":[[2017,10,26]],"date-time":"2017-10-26T09:01:05Z","timestamp":1509008465000},"page":"905-911","source":"Crossref","is-referenced-by-count":29,"title":["Optimizing Somatostatin Receptor Imaging in Patients With Neuroendocrine Tumors"],"prefix":"10.1097","volume":"42","author":[{"given":"Jolanta","family":"Kunikowska","sequence":"first","affiliation":[{"name":"From the *Department of Nuclear Medicine, Medical University of Warsaw, Warsaw, Poland; and \u2020Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Lewington","sequence":"additional","affiliation":[{"name":"From the *Department of Nuclear Medicine, Medical University of Warsaw, Warsaw, Poland; and \u2020Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leszek","family":"Krolicki","sequence":"additional","affiliation":[{"name":"From the *Department of Nuclear Medicine, Medical University of Warsaw, Warsaw, Poland; and \u2020Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"bib1-20231021","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000443167","article-title":"ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site","volume":"103","year":"2016","journal-title":"Neuroendocrinology"},{"key":"bib2-20231021","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1159\/000225951","article-title":"ENETS Consensus Guidelines for the standards of care in neuroendocrine tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs","volume":"90","year":"2009","journal-title":"Neuroendocrinology"},{"key":"bib3-20231021","first-page":"575","article-title":"The value of radiolabeled MIBG and octreotide in the diagnosis and management of neuroendocrine tumours","volume":"55","year":"2001","journal-title":"Clin Endocrinol"},{"key":"bib4-20231021","doi-asserted-by":"crossref","first-page":"26","DOI":"10.7326\/0003-4819-125-1-199607010-00005","article-title":"Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas: a prospective study","volume":"125","year":"1996","journal-title":"Ann Int Med"},{"key":"bib5-20231021","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1530\/ERC-10-0282","article-title":"Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours","volume":"18","year":"2011","journal-title":"Endocr Relat Cancer"},{"key":"bib6-20231021","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s00259-006-0113-7","article-title":"Tc-99m-EDDA\/HYNIC octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years' experience","volume":"33","year":"2006","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib7-20231021","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1016\/j.dld.2003.11.024","article-title":"Diagnostic uses of radiolabelled somatostatin receptor analogues in gastroenteropancreatic endocrine tumours","volume":"36","year":"2004","journal-title":"Dig Liver Dis"},{"key":"bib8-20231021","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1200\/JCO.2005.01.013","article-title":"Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging","volume":"23","year":"2005","journal-title":"J Clin Oncol"},{"key":"bib9-20231021","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2967\/jnumed.106.035667","article-title":"Ga-68-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT","volume":"48","year":"2007","journal-title":"J Nucl Med"},{"key":"bib10-20231021","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1007\/s00259-007-0450-1","article-title":"Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours","volume":"34","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib11-20231021","doi-asserted-by":"crossref","first-page":"875","DOI":"10.2967\/jnumed.109.066134","article-title":"The role of Ga-68 DOTATATE PETin patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy","volume":"51","year":"2010","journal-title":"J Nucl Med"},{"key":"bib12-20231021","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1007\/s00330-015-3882-1","article-title":"Comparison of diagnostic accuracy of 111In-pentetreotide SPECT and Ga-68-DOTATOC PET\/CT: a lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours","volume":"26","year":"2016","journal-title":"Eur Radiol"},{"key":"bib13-20231021","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s13139-015-0356-y","article-title":"Comparison of diagnostic sensitivity and quantitative indices between Ga-68-DOTATOC PET\/CT and 111In-pentetreotide SPECT\/CT in neuroendocrine tumors: a preliminary report","volume":"49","year":"2015","journal-title":"Nucl Med Mol Imaging"},{"key":"bib14-20231021","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.2967\/jnumed.114.144543","article-title":"Ga-68 DOTATATE PET\/CT, Tc-99m-HYNIC-Octreotide SPECT\/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial","volume":"55","year":"2014","journal-title":"J Nucl Med"},{"key":"bib15-20231021","first-page":"273","article-title":"Affinity profiles for human somatostatin receptor subtypes SST1\u2013SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use","volume":"27","year":"2000","journal-title":"Eur J NuclMed"},{"key":"bib16-20231021","first-page":"1114","article-title":"Tc-99m-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor\u2013positive tumors: preclinical evaluation and comparison with 111In-octreotide","volume":"41","year":"2000","journal-title":"J Nucl Med"},{"key":"bib17-20231021","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/MNM.0b013e3282f3a515","article-title":"PET versus SPECT: strengths, limitations and challenges","volume":"29","year":"2008","journal-title":"Nucl Med Commun"},{"key":"bib19-20231021","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.2967\/jnumed.111.091165","article-title":"Ga-68-DOTATOC versus Ga-68 DOTATATE PET\/CT in functional imaging of neuroendocrine tumors","volume":"52","year":"2011","journal-title":"J Nucl Med"},{"key":"bib20-20231021","doi-asserted-by":"crossref","first-page":"364","DOI":"10.2967\/jnumed.112.111724","article-title":"Comparison of Ga-68-DOTANOC and Ga-68 DOTATATE PET\/CT within patients with gastroenteropancreatic neuroendocrine tumors","volume":"54","year":"2013","journal-title":"J Nucl Med"},{"key":"bib21-20231021","first-page":"708","article-title":"Ga-68 DOTATATE compared to 111In-DTPA-octreotide and conventional imaging for pulmonary and gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis","volume":"57","year":"2016","journal-title":"J Nucl Med"},{"key":"bib22-20231021","doi-asserted-by":"crossref","first-page":"855","DOI":"10.2967\/jnumed.112.114165","article-title":"Measured human dosimetry of Ga-68 DOTATATE","volume":"54","year":"2013","journal-title":"J Nucl Med"},{"key":"bib23-20231021","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1007\/s00261-003-0162-3","article-title":"Imaging of neuroendocrine tumors: accuracy of helical CT versus SRS","volume":"29","year":"2004","journal-title":"Abdom Imaging"},{"key":"bib24-20231021","first-page":"1687","article-title":"Somatostatin receptor scintigraphy with 111In-pentetreotide in non-functioning gastroenteropancreatic neuroendocrine tumors","volume":"23","year":"2003","journal-title":"Int J Oncol"},{"key":"bib25-20231021","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1200\/JCO.2015.64.0987","article-title":"Prospective study of Ga-68 DOTATATE positron emission tomography\/computed tomography for detecting gastro-entero-pancreatic neuroendocrine tumors and unknown primary sites","volume":"34","year":"2016","journal-title":"J Clin Oncol"},{"key":"bib26-20231021","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2967\/jnumed.109.071712","article-title":"Ga-68-DOTANOC PET\/CT clinical impact in patients with neuroendocrine tumors","volume":"51","year":"2010","journal-title":"J Nucl Med"},{"key":"bib27-20231021","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1097\/SLA.0b013e3181fd37e8","article-title":"The impact of Ga-68-DOTATOC positron emission tomography\/computed tomography on the multimodal management of patients with neuroendocrine tumors","volume":"252","year":"2010","journal-title":"Ann Surg"},{"key":"bib28-20231021","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000265561","article-title":"Impact of multiphase Ga-68-DOTATOC-PET\/CT on therapy management in patients with neuroendocrine tumors","volume":"91","year":"2010","journal-title":"Neuroendocrinology"},{"key":"bib29-20231021","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.2214\/AJR.11.7298","article-title":"Gallium-68-DOTANOC PET\/CT of patients with gastroenteropancreatic neuroendocrine tumors: a prospective single-center study","volume":"197","year":"2011","journal-title":"AJR Am J Roentgenol"},{"key":"bib30-20231021","article-title":"Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate","volume":"30","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib31-20231021","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1097\/RLU.0b013e31825b2555","article-title":"Semiquantitative analysis and characterization of physiological biodistribution of (68)Ga-DOTA-TATE PET\/CT","volume":"37","year":"2012","journal-title":"Clin Nucl Med"},{"key":"bib32-20231021","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11307-014-0795-3","article-title":"SUV of [Ga-68]DOTATOC-PET\/CT predicts response probability of PRRT in neuroendocrine tumors","volume":"17","year":"2015","journal-title":"Mol Imaging Biol"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00003072-201712000-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T04:27:43Z","timestamp":1697862463000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003072-201712000-00001"}},"subtitle":["The Impact of 99mTc-HYNICTOC SPECT\/SPECT\/CT Versus 68Ga-DOTATATE PET\/CT Upon Clinical Management"],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000001877","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]}}}